Abstract
Some individuals who initiate highly active antiretroviral therapy (HAART) develop new or worsening opportunistic infections or malignancies despite improvements in surrogate markers of HIV-1 infection. These events of paradoxical clinical worsening, also known as immune reconstitution syndromes (IRS), are increased in individuals with prior opportunistic infections or low CD4+ T-cell nadirs. They are thought to result from reconstitution of the immune system’s ability to recognize pathogens or tumor antigens that were previously present, but clinically asymptomatic. There is no consensus regarding the diagnostic criteria or pathogenesis of IRS. Knowledge of their presentation and treatment is largely based on case reports. With the introduction of HAART into resource-limited settings, it is likely that significantly more and distinct forms of IRS will be observed. Prospective studies of the incidence and treatment of IRS in multiple settings are critical to better understand their pathogenesis and optimal management.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860.
Hirsch HH, Kaufmann G, Sendi P, Battegay M: Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004, 38:1159–1166.
French MA, Lenzo N, John M, et al.: Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000, 1:107–115. This paper estimates the incidence of IRS to be 25% in HAART responders. It contains a detailed discussion of each event and correlates events with pathogen-specific immune responses.
Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al.: Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002, 81:213–227.
Cheng VC, Yuen KY, Chan WM, et al.: Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 2000, 30:882–892.
French MA, Mallal SA, Dawkins RL: Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992, 6:1293–1297.
French MA, Price P, Stone SF: Immune restoration disease after antiretroviral therapy. AIDS 2004, 18:1615–1627.
Cooney EL: Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis 2002, 34:224–233.
Shelburne SA 3rd, Hamill RJ: The immune reconstitution inflammatory syndrome. AIDS Rev 2003, 5:67–79.
DeSimone JA, Pomerantz RJ, Babinchak TJ: Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000, 133:447–454.
Autran B, Carcelaint G, Li TS, et al.: Restoration of the immune system with anti-retroviral therapy. Immunol Lett 1999, 66:207–211.
Komanduri KV, Viswanathan MN, Wieder ED, et al.: Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998, 4:953–956.
Connick E, Lederman MM, Kotzin BL, et al.: Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000, 181:358–363.
Sungkanuparph S, Vibhagool A, Mootsikapun P, et al.: Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS 2003, 17:2129–2131.
Race EM, Adelson-Mitty J, Kriegel GR, et al.: Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998, 351:252–255.
Di Perri G, Bonora S, Vento S, et al.: Highly active antiretroviral therapy. Lancet 1998, 351:1056; author reply 1058–1059.
Dworkin MS, Fratkin MD: Mycobacterium avium complex lymph node abscess after use of highly active antiretroviral therapy in a patient with AIDS. Arch Intern Med 1998, 158:1828.
Cabie A, Abel S, Brebion A, et al.: Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 1998, 17:812–813.
Foudraine NA, Hovenkamp E, Notermans DW, et al.: Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13:177–184.
Phillips P, Kwiatkowski MB, Copland M, et al.: Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:122–128.
del Giudice P, Durant J, Counillon E, et al.: Mycobacterial cutaneous manifestations: a new sign of immune restoration syndrome in patients with acquired immunodeficiency syndrome. Arch Dermatol 1999, 135:1129–1130.
Price LM, O’Mahony C: Focal adenitis developing after immune reconstitution with HAART. Int J STD AIDS 2000, 11:685–686.
Aberg JA, Chin-Hong PV, McCutchan A, et al.: Localized osteomyelitis due to Mycobacterium avium complex in patients with human immunodeficiency virus receiving highly active antiretroviral therapy. Clin Infect Dis 2002, 35:E8-E13.
Buckingham SJ, Haddow LJ, Shaw PJ, Miller RF: Immune reconstitution inflammatory syndrome in HIV-infected patients with mycobacterial infections starting highly active anti-retroviral therapy. Clin Radiol 2004, 59:505–513.
Behrens GM, Meyer D, Stoll M, Schmidt RE: Immune reconstitution syndromes in human immunodeficiency virus infection following effective antiretroviral therapy. Immunobiology 2000, 202:186–193.
Powles T, Thirlwell C, Nelson M, Bower M: Immune reconstitution inflammatory syndrome mimicking relapse of AIDS related lymphoma in patients with HIV 1 infection. Leuk Lymphoma 2003, 44:1417–1419.
Lawn SD, Bicanic TA, Macallan DC: Pyomyositis and cutaneous abscesses due to Mycobacterium avium: an immune reconstitution manifestation in a patient with AIDS. Clin Infect Dis 2004, 38:461–463.
Michelet C, Arvieux C, Francois C, et al.: Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998, 12:1815–1822.
Cinti SK, Kaul DR, Sax PE, et al.: Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis 2000, 30:511–514.
Brown M, Williams IG, Miller RF: Deterioration of disseminated cutaneous Mycobacterium avium complex infection with a leukaemoid reaction following institution of highly active antiretroviral therapy. Sex Transm Infect 2001, 77:149–150.
Murray R, Mallal S, Heath C, French M: Cerebral mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated mycobacterium avium complex infection. Eur J Clin Microbiol Infect Dis 2001, 20:199–201.
Cheng VC, Yam WC, Woo PC, et al.: Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis 2003, 22:597–602.
Burman WJ, Jones BE: Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001, 164:7–12.
Narita M, Ashkin D, Hollender ES, Pitchenik AE: Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998, 158:157–161.
Navas E, Martin-Davila P, Moreno L, et al.: Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002, 162:97–99.
Breen RA, Smith CJ, Bettinson H, et al.: Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004, 59:704–707. This study determined the frequency of MTB IRS to be 29% in patients with known HIV-MTB coinfection. The authors correlated it with earlier initiation of HAART after MTB diagnosis.
Wendel KA, Alwood KS, Gachuhi R, et al.: Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001, 120:193–197.
Orlovic D, Smego RA Jr: Paradoxical tuberculous reactions in HIV-infected patients. Int J Tuberc Lung Dis 2001, 5:370–375.
Goldsack NR, Allen S, Lipman MC: Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect 2003, 79:337–338.
Crump JA, Tyrer MJ, Lloyd-Owen SJ, et al.: Military tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 1998, 26:1008–1009.
Guex AC, Bucher HC, Demartines N, et al.: Inflammatory bowel perforation during immune restoration after one year of antiretroviral and antituberculous therapy in an HIV-1-infected patient: report of a case. Dis Colon Rectum 2002, 45:977–978.
John M, French MA: Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998, 169:473–474.
Chien JW, Johnson JL: Paradoxical reactions in HIV and pulmonary TB. Chest 1998, 114:933–936.
Furrer H, Malinverni R: Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Am J Med 1999, 106:371–372.
Fishman JE, Saraf-Lavi E, Narita M, et al.: Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000, 174:43–49.
Lawn SD, Macallan DC: Hypercalcemia: a manifestation of immune reconstitution complicating tuberculosis in an HIVinfected person. Clin Infect Dis 2004, 38:154–155.
Hollender ES, Narita M, Ashkin D, et al.: CNS manifestations of paradoxical reaction in HIV+ TB patients on HAART. Paper presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; January 30-February 2, 2000.
Trevenzoli M, Cattelan AM, Rea F, et al.: Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era. J Infect 2002, 45:173–179.
Jenny-Avital ER, Abadi M: Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002, 35:e128-e133.
Cattelan AM, Trevenzoli M, Sasset L, et al.: Multiple cerebral cryptococcomas associated with immune reconstitution in HIV-1 infection. AIDS 2004, 18:349–351.
Cinti SK, Armstrong WS, Kauffman CA: Case report. Recurrence of increased intracranial pressure with antiretroviral therapy in an AIDS patient with cryptococcal meningitis. Mycoses 2001, 44:497–501.
Lanzafame M, Trevenzoli M, Carretta G, et al.: Mediastinal lymphadenitis due to cryptococcal infection in HIV-positive patients on highly active antiretroviral therapy. Chest 1999, 116:848–849.
Woods ML 2nd, MacGinley R, Eisen DP, Allworth AM: HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998, 12:1491–1494.
Blanche P, Gombert B, Ginsburg C, et al.: HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Scand J Infect Dis 1998, 30:615–616.
Manfredi R, Pieri F, Pileri SA, Chiodo F: The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review. Mycopathologia 1999, 148:73–78.
Rambeloarisoa J, Batisse D, Thiebaut JB, et al.: Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS. J Infect 2002, 44:185–188.
Breton G, Seilhean D, Cherin P, et al.: Paradoxical intracranial cryptococcoma in a human immunodeficiency virus-infected man being treated with combination antiretroviral therapy. Am J Med 2002, 113:155–157.
King MD, Perlino CA, Cinnamon J, Jernigan JA: Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Int J STD AIDS 2002, 13:724–726.
Legendre U, Battegay M, Nuttli I, et al.: Simultaneous occurrence of 2 HIV-related immunereconstitution diseases after initiation of highly active antiretroviral therapy. Scand J Infect Dis 2001, 33:388–389.
Dean GL, Williams DI, Churchill DR, Fisher MJ: Transient clinical deterioration in HIV patients with Pneumocystis carinii pneumonia after starting highly active antiretroviral therapy: another case of immune restoration inflammatory syndrome. Am J Respir Crit Care Med 2002, 165:1670; author reply 1670.
Wislez M, Bergot E, Antoine M, et al.: Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001, 164:847–851.
Lim L, Street AC, Lewin SR: Pneumocystis carinii pneumonia after cessation of secondary prophylaxis in a patient on highly active antiretroviral therapy with a CD4 cell count greater than 200/mm3. AIDS 2001, 15:1912–1913.
Koval CE, Gigliotti F, Nevins D, Demeter LM: Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 2002, 35:491–493.
Atzori C, Clerici M, Trabattoni D, et al.: Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. J Antimicrob Chemother 2003, 52:276–281.
Bozzette SA, Sattler FR, Chiu J, et al.: A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990, 323:1451–1457.
Casado JL, Arrizabalaga J, Montes M, et al.: Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMVAIDS Study Group. AIDS 1999, 13:1497–1502.
Gilquin J, Piketty C, Thomas V, et al.: Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 x 10(6) cells/l following combination antiretroviral therapy including protease inhibitors. AIDS 1997, 11:1659–1660.
Nguyen QD, Kempen JH, Bolton SG, et al.: Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000, 129:634–639.
Karavellas MP, Lowder CY, Macdonald C, et al.: Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998, 116:169–175.
Jouan M, Saves M, Tubiana R, et al.: Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2001, 15:23–31.
Karavellas MP, Plummer DJ, Macdonald JC, et al.: Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999, 179:697–700.
Deayton JR, Wilson P, Sabin CA, et al.: Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000, 14:1163–1170.
Nguyen QD, Kempen JH, Bolton SG, et al.: Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000, 129:634–639.
Stone SF, Price P, Tay-Kearney ML, French MA: Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 2002, 185:1813–1817.
Karavellas MP, Song M, Macdonald JC, Freeman WR: Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am J Ophthalmol 2000, 130:57–64.
Zegans ME, Walton RC, Holland GN, et al.: Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998, 125:292–300.
Sanislo SR, Lowder CY, Kaiser PK: Optic nerve head neovascularization in a patient with inactive cytomegalovirus retinitis and immune recovery. Am J Ophthalmol 1998, 126:318–320.
Boyraz-Ikiz HD, Witmer JP, Frissen PH: Cytomegalovirus (re)activation plays no role in the ocular vitritis observed after initiation of highly active antiretroviral therapy. AIDS 1999, 13:867.
Miller RF, Shaw PJ, Williams IG: Immune reconstitution CMV pneumonitis. Sex Transm Infect 2000, 76:60.
Whitcup SM: Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA 2000, 283:653–657.
Jacobson MA, Zegans M, Pavan PR, et al.: Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997, 349:1443–1445.
Mayo J, Collazos J, Martinez E: Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy. AIDS 1998, 12:1720–1722.
Kotecha N, George MJ, Smith TW, et al.: Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med 1998, 105:541–543.
Tantisiriwat W, Tebas P, Clifford DB, et al.: Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 1999, 28:1152–1154.
Collazos J, Mayo J, Martinez E, Blanco MS: Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 1999, 13:1426–1428.
Giudici B, Vaz B, Bossolasco S, et al.: Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 2000, 30:95–99.
De Luca A, Giancola ML, Ammassari A, et al.: The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDSassociated progressive multifocal leukoencephalopathy. J Infect Dis 2000, 182:1077–1083.
Miralles P, Berenguer J, Lacruz C, et al.: Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 2001, 15:1900–1902.
Safdar A, Rubocki RJ, Horvath JA, et al.: Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002, 35:1250–1257.
Hoffmann C, Horst HA, Albrecht H, Schlote W: Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003, 74:1142–1144.
Albrecht H, Hoffmann C, Degen O, et al.: Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998, 12:1149–1154.
Puoti M, Torti C, Ripamonti D, et al.: Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003, 32:259–267.
Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74–80.
Wit FW, Weverling GJ, Weel J, et al.: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002, 186:23–31.
Puoti M, Gargiulo F, Roldan EQ, et al.: Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis 2000, 181:2033–2036.
Velasco M, Moran A, Tellez MJ: Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med 1999, 340:1765–1766.
Carr A, Cooper DA: Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997, 349:995–996.
Manegold C, Hannoun C, Wywiol A, et al.: Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001, 32:144–148.
Proia LA, Ngui SL, Kaur S, et al.: Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy. Am J Med 2000, 108:249–251.
Drake A, Mijch A, Sasadeusz J: Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004, 39:129–132.
Mastroianni CM, Trinchieri V, Santopadre P, et al.: Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. AIDS 1998, 12:1939–1940.
John M, Flexman J, French MA: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998, 12:2289–2293.
Zylberberg H, Pialoux G, Carnot F, et al.: Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998, 27:1255–1258.
Pol S, Lebray P, Vallet-Pichard A: HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 2004, 38(Suppl 2):S65-S72.
Uberti-Foppa C, De Bona A, Morsica G, et al.: Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 33:146–152.
Martinez E, Gatell J, Moran Y, et al.: High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998, 27:1510–1513.
Aldeen T, Hay P, Davidson F, Lau R: Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy. AIDS 1998, 12:1719–1720.
Domingo P, Torres OH, Ris J, Vazquez G: Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med 2001, 110:605–609.
Naseri A, Margolis TP: Varicella zoster virus immune recovery stromal keratitis in a patient with AIDS. Br J Ophthalmol 2001, 85:1390–1391.
Clark BM, Krueger RG, Price P, French MA: Compartmentalization of the immune response in varicella zoster virus immune restoration disease causing transverse myelitis. AIDS 2004, 18:1218–1221.
Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, et al.: Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol 2004, 113:742–746.
Greenspan D, Canchola AJ, MacPhail LA, et al.: Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001, 357:1411–1412.
King MD, Reznik DA, O’Daniels CM, et al.: Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002, 34:641–648.
Hagensee ME, Cameron JE, Leigh JE, Clark RA: Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004, 328:57–63.
Heard I, Palefsky JM, Kazatchkine MD: The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004, 9:13–22.
Cattelan AM, Calabro ML, Aversa SM, et al.: Regression of AIDS-related Kaposi’s sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999, 35:1809–1815.
Lebbe C, Blum L, Pellet C, et al.: Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS 1998, 12:F45-F49.
Weir A, Wansbrough-Jones M: Mucosal Kaposi’s sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997, 11:1895–1896.
Connick E, Kane MA, White IE, et al.: Immune reconstitution inflammatory syndrome (IRIS) to Kaposi’s sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004, In press.
Rizos E, Drosos AA, Ioannidis JP: Isolated intraparotid Kaposi sarcoma in human immunodeficiency virus type 1 infection. Mayo Clin Proc 2003, 78:1561–1563.
Price P, Morahan G, Huang D, et al.: Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002, 16:2043–2047.
Price P, Keane NM, Stone SF, et al.: MHC haplotypes affect the expression of opportunistic infections in HIV patients. Hum Immunol 2001, 62:157–164.
Stone SF, Price P, Brochier J, French MA: Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virusinfected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis 2001, 184:1073–1077.
Rutschmann OT, Negro F, Hirschel B, et al.: Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998, 177:783–785.
Blanche P, Gombert B, Rivoal O, et al.: Uveitis due to Leishmania major as part of HAART-induced immune restitution syndrome in a patient with AIDS. Clin Infect Dis 2002, 34:1279–1280.
Lawn SD, Wood C, Lockwood DN: Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin Infect Dis 2003, 36:e5-e6.
Collazos J, Ojanguren J, Mayo J, et al.: Lymphoma developing shortly after the onset of highly active antiretroviral therapy in HIV-infected patients. AIDS 2002, 16:1304–1306.
Mirmirani P, Maurer TA, Herndier B, et al.: Sarcoidosis in a patient with AIDS: a manifestation of immune restoration syndrome. J Am Acad Dermatol 1999, 41:285–286.
Piliero PJ, Fish DG, Preston S, et al.: Guillain-Barre syndrome associated with immune reconstitution. Clin Infect Dis 2003, 36:e111-e114.
Jubault V, Penfornis A, Schillo F, et al.: Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 2000, 85:4254–4257.
Sereti I, Sarlis NJ, Arioglu E, et al.: Alopecia universalis and Graves’ disease in the setting of immune restoration after highly active antiretroviral therapy. AIDS 2001, 15:138–140.
French MA, Lewin SR, Dykstra C, et al.: Graves’ disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Res Hum Retroviruses 2004, 20:157–162.
Silvestre JF, Albares MP, Ramon R, Botella R: Cutaneous intolerance to tattoos in a patient with human immunodeficiency virus: a manifestation of the immune restoration syndrome. Arch Dermatol 2001, 137:669–670.
Fox PA, Barton SE, Francis N, et al.: Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med 1999, 1:10–18.
Nolan RC, Chidlow G, French MA: Parvovirus B19 encephalitis presenting as immune restoration disease after highly active antiretroviral therapy for human immunodeficiency virus infection. Clin Infect Dis 2003, 36:1191–1194.
Abino JF, Peraldi R, Lepidi H, et al.: Bacillary splenitis (Bartonella henselae) during immune restoration in an HIV-infected patient. AIDS 2002, 16:1429–1430.
Bouscarat F, Maubec E, Matheron S, Descamps V: Immune recovery inflammatory folliculitis. AIDS 2000, 14:617–618.
Berry A, Abraham B, Dereure J, et al.: Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy. Scand J Infect Dis 2004, 36:225–227.
Fernando R, Miller R: Immune reconstitution eosinophilia due to schistosomiasis. Sex Transm Infect 2002, 78:76.
Gajdatsy AD, Tay-Kearney ML: Microsporidial keratoconjunctivitis after HAART. Clin Experiment Ophthalmol 2001, 29:327–329.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gardner, E.M., Connick, E. Illness of immune reconstitution: Recognition and management. Curr Infect Dis Rep 6, 483–493 (2004). https://doi.org/10.1007/s11908-004-0068-4
Issue Date:
DOI: https://doi.org/10.1007/s11908-004-0068-4